Latest Clinical News

20-Year Data Link High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant to Survival Benefit in High-Risk Early Breast Cancer (10-31-2018)

Adjuvant high-dose chemotherapy (HDCT) with hematopoietic stem cell transplant (HSCT) may be beneficial for patients with breast cancer and more than 9 involved axially lymph nodes (ALN), according to a study presented at the 2018 ESMO Congress in Munich,... Continue Reading

New Treatment Approved for Influenza (10-26-2018)

The Food and Drug Administration (FDA) has approved Xofluza (baloxavir marboxil) for the treatment of acute uncomplicated influenza in patients aged ≥12 years old who have been symptomatic for no more than 48 hours. Xofluza is a first-in-class, single-dose... Continue Reading

November Is National Lung Cancer Awareness Month (10-23-2018)

Treatment advances – lung cancer resources and advocacy are making the difference The month of November brings lung cancer into focus. Over the past few years great strides have been made in the treatment of non-small cell lung cancer due to the... Continue Reading

Laurie MacCaskill Partners with CancerConnect (10-19-2018)

KETCHUM – LOS ANGELES: Laurie MacCaskill, a 12-year survivor of pancreatic cancer and former chair of the Pancreatic Cancer Action Network has announced a newly established partnership with Cancer Connect to support pancreatic cancer patients with information,... Continue Reading

Blood Test Identifies More Treatable Cancer Mutations Than Tissue Biopsy Alone (10-15-2018)

Penn study shows patients with treatable mutations identified by liquid biopsy also largely respond to therapy October 11, 2018 PHILADELPHIA – In one of the largest clinical studies to ever examine the impact of using a blood test to detect treatable... Continue Reading

More women with early-stage breast cancer may be able to avoid chemotherapy (10-10-2018)

Results from a large clinical trial called TAILORx showed that more women with early-stage breast cancer may now be able to avoid chemotherapy after surgery. The women who participated in the study had hormone receptor-positive, HER2-negative, axillary... Continue Reading

Designation for Advanced Cutaneous Squamous Cell Carcinoma (10-1-2018)

Breakthrough Designation for Advanced Cutaneous Squamous Cell Carcinoma The U.S. Food and Drug Administration (FDA) has approved cemiplimab (REGN2810) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (CSCC) and adults with... Continue Reading

duvelisib (COPIKTRA, Verastem, Inc.) for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) (09-25-2018)

The Food and Drug Administration granted regular approval to duvelisib (COPIKTRA, Verastem, Inc.) for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies. In... Continue Reading

Clinical Trial Shows Best Outcomes to Date for Older Hodgkin Lymphoma Patients (09-18-2018)

Recently published results of a phase 2 clinical trial have shown the best outcomes to date for newly diagnosed older Hodgkin lymphoma patients treated with brentuximab vedotin given before and after doxorubicin, vinblastine and dacarbazine (AVD) chemotherapy,... Continue Reading

First In Class Immunostimulating Anticancer Agent able to Directly Inhibit Tumor Signaling and Kill Tumor Cells, is in Clinical Trial for Glioblastoma and Melanoma Metastatic to the Brain (09-13-2018)

Small molecule lead drug candidate blocks a critical target for tumors and crosses the blood brain barrier; begins first brain cancer patient dosing in clinical trial at MD Anderson Cancer Center HOUSTON, TX – September 13, 2018 – In the ongoing... Continue Reading

Targeted Combination Treatment for Melanoma now Available (09-10-2018)

The US Food and Drug Administration (FDA) approved the combination of Bratovi (encorafenib) and Mektovi (binimetinib)for use in patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. About... Continue Reading

AbbVie Announces IMBRUVICA® (ibrutinib) Plus Rituximab Approval by U.S. FDA as First Chemotherapy-Free Combination Treatment in Adults with Waldenström’s Macroglobulinemia, a Rare Type of Blood Cancer (09-4-2018)

PRESS RELEASE PR Newswire Aug. 27, 2018, 07:00 AM NORTH CHICAGO, Ill., Aug. 27, 2018 /PRNewswire/ — AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved... Continue Reading

« Previous PageNext Page »